Results 151 to 160 of about 3,576,624 (253)

autoscoRA: Deep Learning to Automate Sharp/van der Heijde Scoring of Radiographic Damage in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Regular imaging by conventional radiography to assess for joint damage is a cornerstone in the management of rheumatoid arthritis. Scoring systems to quantify such damage, such as the widely used Sharp/van der Heijde (SvdH) score, are limited by the requirement of time and experienced staff as well as intra‐ and interrater variability.
Thomas Deimel   +6 more
wiley   +1 more source

Developing the infrastructure for patient review in academic journals. [PDF]

open access: yesRes Involv Engagem, 2018
Staniszewska S, Stephens R, Flemyng E.
europepmc   +1 more source

Gender Equity in Rheumatology Research: Global Analysis of Authors

open access: yesArthritis &Rheumatology, EarlyView.
Objective To investigate gender representation of authors in rheumatology research over the last decade. Methods Using metadata from original and review articles published between 2015 and 2024 in SCImago top two quartile (Q1, Q2) rheumatology journals, author gender was classified using two public databases.
Michael Girdwood   +7 more
wiley   +1 more source

Human Fibroblast–Myeloid Cell Tissue Atlas Across the Lungs, Synovium, Skin, and Heart

open access: yesArthritis &Rheumatology, EarlyView.
Objective The availability of single‐cell RNA sequencing (scRNAseq) data in different tissues and disease states provides an opportunity to compare cellular subsets and identify common and unique cellular activation. In this study, we aimed to characterize shared and tissue‐specific myeloid and stromal phenotypes and to uncover key cellular subtypes ...
Lucy MacDonald   +9 more
wiley   +1 more source

Homocitrullinated Peptides Drive Pro‐Inflammatory T Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova   +6 more
wiley   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

open access: yesArthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf   +15 more
wiley   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian   +8 more
wiley   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner   +52 more
wiley   +1 more source

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

open access: yesArthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy